# A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors

> **NCT02913313** · PHASE1,PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 101 (actual)

## Conditions studied

- Broad Solid Tumor

## Interventions

- **DRUG:** BMS-986207
- **BIOLOGICAL:** Nivolumab
- **BIOLOGICAL:** Ipilimumab

## Key facts

- **NCT ID:** NCT02913313
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11-30
- **Primary completion:** 2024-01-25
- **Final completion:** 2024-01-25
- **Target enrollment:** 101 (ACTUAL)
- **Last updated:** 2025-04-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02913313

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02913313, "A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02913313. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*